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TUTORIAL
Assay Guidance Manual: Quantitative Biology
and Pharmacology in Preclinical Drug Discovery
Nathan P. Coussens1,∗, G. Sitta Sittampalam1,∗, Rajarshi Guha1, Kyle Brimacombe1, Abigail Grossman1, Thomas D. Y. Chung2,
Jeffrey R. Weidner3, Terry Riss4, O. Joseph Trask5, Douglas Auld6, Jayme L. Dahlin7, Viswanath Devanaryan8, Timothy L. Foley9,
James McGee10, Steven D. Kahl10, Stephen C. Kales1, Michelle Arkin11, Jonathan Baell12, Bruce Bejcek13, Neely Gal-Edd14,
Marcie Glicksman15, Joseph V. Haas10, Philip W. Iversen10, Marilu Hoeppner16, Stacy Lathrop16, Eric Sayers16, Hanguan Liu16,
Bart Trawick16, Julie McVey16, Vance P. Lemmon17, Zhuyin Li18, Owen McManus19, Lisa Minor20, Andrew Napper21,
Mary Jo Wildey22, Robert Pacifici23, William W. Chin24, Menghang Xia1, Xin Xu1, Madhu Lal-Nag1, Matthew D. Hall1, Sam Michael1,
James Inglese1, Anton Simeonov1 and Christopher P. Austin1
The Assay Guidance Manual (AGM) is an eBook of best practices for the design, development, and imple-
mentation of robust assays for early drug discovery. Initiated by pharmaceutical company scientists,
the manual provides guidance for designing a “testing funnel” of assays to identify genuine hits using
high-throughput screening (HTS) and advancing them through preclinical development. Combined with a
workshop/tutorial component, the overall goal of the AGM is to provide a valuable resource for training
translational scientists.
Clin Transl Sci (2018)
MEASUREMENT TECHNOLOGIES IN TRANSLATIONAL
SCIENCES: QUANTITATIVE BIOLOGY AND
PHARMACOLOGY
Advances in basic research among academia and small
biotech startups have led to proposals of innovative thera-
peutic approaches to help address unmet medical needs.
However, a large gap exists between the basic research con-
ducted in such organizations and the translation of those
fundamental advances into therapeutics that historically has
remained the expertise of large pharmaceutical companies.
This situation is changing with the development of collab-
oration models involving government, academia, industry,
and disease philanthropy. Moreover, there is an evolving
paradigm for drug discovery and early development within
the academic sector as universities are increasingly focusing
on commercializing research. While translational scientists
were historically trained within the pharmaceutical industry,
the newer public-private collaborative models of drug dis-
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covery necessitate training opportunities for scientists work-
ing in the public sector.
The reasons for clinical failures are manifold and com-
plex, and factors include: choices made at the discovery
phase of lead identification and optimization, poor under-
standing of disease pathogenesis, poor pharmacokinetics
(PKs)/pharmacodynamics, nonpredictive animal models,
poor trial design, wrong patient population genetics and
demographics, toxicity associated with modulation of the
target, wrong outcome measures, as well as changing
business and financial priorities.1 Recent publications have
highlighted the need to train health professionals to appreci-
ate the complexities throughout the translational continuum
so that they can address deficiencies in the process and
improve the likelihood of clinical success.2,3 The concept of
quantitative biology and pharmacology was developed early
in many pharmaceutical research laboratories with a goal
of successfully translating basic biology into viable drug
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discovery projects. The practice of quantitative biology and
pharmacology requires a multidisciplinary approach span-
ning basic cell biology, biochemistry, chemistry, physics,
pharmacology, engineering, statistics, automation, and infor-
mation technology, while encompassing concepts in the
subdisciplines of bioanalytical chemistry and bioanalysis.
This practice is particularly important in developing biologi-
cally, physiologically, and pharmacologically relevant assays.
Similarly, there have been multidisciplinary approaches to
developments in novel signal generation and detection tech-
nologies, cellular biology methodologies, liquid handling,
miniaturization, data analysis, and engineering systems solu-
tions. Advances in these technologies and their adoption
into the practice of quantitative biology and pharmacology
have necessitated a different medium than traditional books
and compendia for training translational scientists.
The Assay Guidance Manual (AGM) was developed to pro-
vide researchers with best-practice guidelines and quanti-
tative biology and pharmacology concepts for robust assay
development, and was utilized to train therapeutic area sci-
entists in its original version at Eli Lilly & Company and
Sphinx Pharmaceuticals. The AGM has been a free and
publicly available resource since 2005, currently acces-
sible as an eBook on the National Library of Medicine
(NLM), National Center for Biotechnology Information (NCBI)
Bookshelf (www.ncbi.nlm.nih.gov/books/NBK53196).4 In its
current form as a dynamic, readily updatable eBook with
continued renewal and expansion of content, the AGM is
widely accessed (>30,000 views/month in 2017) by sci-
entists from pharma, biotech, government, and academic
research laboratories. Although assay development is a basic
skill that is addressed throughout the biomedical curricula,
advances in assay technologies, instrumentation, and analyt-
ical technologies, in addition to data acquisition and analysis
software for large data sets, require constant adoption and
training in research laboratories. Therefore, one-time training
during undergraduate or graduate education is inadequate
in the long run. In this tutorial, we describe how the AGM
contributes to the training and education of translational sci-
entists. Chapters of the AGM provide guidelines on a wide
range of topics spanning preclinical development and usage
of the different chapters indicates areas of interest among
drug discovery scientists. This information has contributed
to the development of assay guidance workshops that are
based on critical concepts from the AGM. Ten workshops
have been conducted throughout the United States since
2015 and both the attendance and demand have remained
high. Our vision is for the AGM to serve as a reliable and
comprehensive resource maintained by the drug discovery
community for training translational scientists worldwide.
BIOLOGICAL, PHYSIOLOGICAL, AND
PHARMACOLOGICAL RELEVANCE
The AGM addresses the “nuts and bolts” of designing and
validating biologically and physiologically relevant assays
used throughout the preclinical discovery phase. Validity,
reproducibility, and stability of these measurements are crit-
ical in high-throughput screening (HTS), hit validation, lead
optimization, and regulatory enabling studies to advance dis-
covery projects effectively. This level of reliability is impor-
tant because HTS involves testing large libraries of molecules
with considerable investment in resources, such as reagents,
compound management, automation, acquisition, data stor-
age, and the analysis of millions of data points. Ultimately, the
quality and reliability of this discovery process determines
whether drug leads and candidates are identified and con-
firmed, and the choices made at this stage set the course
of drug development. The AGM aims to reduce the amount
of “garbage-in, garbage-out” by helping researchers develop
assays that have biological relevance and superior perfor-
mance metrics.
It is important to clearly define what significance and
relevance mean in assay design and implementation. The
term significance should be used in the context of statisti-
cal hypothesis testing. Statistical significance is a measure
of how likely an observed result could have occurred on
the basis of a set of assumptions.5 For instance, an event
that is statistically significant is unlikely to have occurred
by chance alone. Biological relevance of an event in any
system (i.e., biochemical, cellular, tissue, and organism) is
defined as being considered by expert judgment as impor-
tant or meaningful.6 It is critical to consider the size and
duration of the event that would be considered biologically
relevant at the design stage of the assay before the pro-
cess of decision making begins. The assay then needs to
be optimized to measure the predefined biologically rele-
vant event with sufficient statistical power to allow detec-
tion of the event if it occurs. The biological event generally
will only be physiologically relevant if the genetic and bio-
chemical behavior is modified, resulting in an observable and
measurable phenotypic outcome related to the living sys-
tem. Here, one could cite how carcinogens and other toxi-
cants induce cell proliferation, tumor development, or result
in cytotoxicity. Physiological relevance implies that appropri-
ate biological systems (e.g., cells, tissues, and animal mod-
els) are used in the testing process and the magnitude of
measured effects is in a physiological range to draw valid
conclusions about the disease pathology. Pharmacological
relevance implies that an agent at the appropriate dose and
exposure can affect the biology to favorably alter phenotype
and patient outcomes associated with the disease hypothe-
sis. In all these cases, the biological, physiological, and phar-
macological effects should be reproducible and measured
quantitatively with statistical significance to ensure reliable
decision making. Hence, the analytical measurement proce-
dures need to be carefully designed to optimize assays that
can be affected by reagents, instrumentation, interference
and artifacts, automation, test compounds, controls, and
data analysis models. This integrated approach to the devel-
opment of assays that support preclinical discovery was rec-
ognized as a critical skill when HTS, hit validation, and lead
optimization practices were developing in the early 1990s.
HISTORY OF THE AGM AND THE NCBI/NLM EBOOK
In the late 1980s and early 1990s, the advent of combinato-
rial chemistry – capable of providing compound libraries with
>100,000 members – and the ability to synthesize hundreds
of molecules in parallel fueled the growth of large compound
collections and demanded higher throughput methods
in biological and pharmacological testing. In response to
Clinical and Translational Science
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this need, automated HTS platform and lead optimiza-
tion approaches were developed in the mid-to-late 1990s
incorporating robotics, workstations, and new assay tech-
nologies using 96-well, 384-well, and 1536-well microtiter
plates and miniaturized assay volumes (<10 μL). In parallel,
informatic tools to acquire, store, and analyze millions of
data points were also developed. Automation coupled to
powerful computing technologies was critical for success
and served as a unique enabler to ensure the development
and implementation of rigorous and reproducible bioas-
say methodologies. Many of the technologies and statistical
tools that were developed within the pharmaceutical industry
in collaboration with instrument and software vendors were
retained as internal proprietary knowledge to drive projects
in preclinical discovery (personal communications with D.
Auld of the Novartis Institutes of Biomedical Research).
A major goal was to develop and validate “automatable
bioassays,” taking benchtop assays built in-house or from
the scientific literature and optimizing these for automated
protocols. This goal also required significant assay and
technology development, as many assays published in the
scientific literature were not amenable to automation.
Some of the AGM chapters were originally developed
as Validation Checklist and Guidelines for High-Throughput
Screening in 1995 and later as the Quantitative Biology
Manual at Eli Lilly and Company and Sphinx Pharmaceuti-
cals in the late 1990s. Contributions came from well over
100 internal scientists involved in drug discovery and devel-
opment. The manual evolved continuously over time and
became a valuable reference within Lilly Research Labora-
tories. The focus was on basic information about biochemi-
cal, cell-based, and in vitro assay technologies that could be
implemented to successfully screen drug targets and path-
ways against small molecule libraries. In addition, the manual
addressed best practices in HTS scale-up, assay operations,
reagent selection, statistical tools for assay validation, and
data analysis and management.
As the National Institutes of Health (NIH) Molecular
Libraries Roadmap program developed in 2003,7,8 discus-
sions between the National Human Genome Research Insti-
tute (NHGRI) and Lilly management resulted in an agreement
to publish this manual on the National Center for Chemi-
cal Genomics website at the NHGRI to share the informa-
tion with academic scientists in the precompetitive space.
The manual was ultimately released to share best practices
in quantitative biology and guidelines for the development
of robust assay methods with the drug discovery commu-
nity as well as enhance academic-industrial collaborations
in translational biology and medicine. Additionally, the man-
ual was intended to grow with the collective experiences and
contributions from public and private research laboratories.
The decision was prescient, particularly given that theMolec-
ular Libraries Roadmap established a number of collabo-
rative HTS centers in the United States that would require
academic laboratories to propose and develop high-quality
screening assays. Sharing precompetitive knowledge con-
tained in the AGM with academic screening laboratories and
the wider scientific community was envisaged to remove bar-
riers to robust discovery assay development, and act as a
catalyst to advance translational science broadly.
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Figure 1 Diversity of the Assay Guidance Manual Editorial Board.
The content of the Assay Guidance Manual is managed by an edi-
torial board of 34 members, most with over 20 years of experience
in drug discovery and development. The editors work in differ-
ent settings including industry, academia, and nonprofit research
institutes.
As drug discovery technologies and methodologies con-
tinued to evolve, it was obvious that the manual required
regular updates and the addition of new content. To accom-
plish this task, an informal steering group of scientists from
the NHGRI-National Center for Chemical Genomics and Eli
Lilly was assembled to administer the updates. The steering
group decided early on that wider participation from phar-
maceutical and academic scientists would further enhance
the value of the AGM. It was also decided that the AGM con-
tent should be managed by an editorial board. In 2012, the
manual became part of an eBook collection on the NLM,
NCBI Bookshelf. This platform had several advantages: (i)
the ability to reach a worldwide audience; (ii) PubMed cita-
tions for the authors who contribute chapters; and (iii) the
eBook chapter formats would be dynamic and, thus, allow
for updates and edits to all chapters through a centralized
submission process to maintain high quality and currency.
The current AGM Editorial Board consists of 34 editors, most
with over 20 years of experience in drug discovery and assay
development from industry, academia, and various research
institutes throughout the world (Figure 1). The editors hold
monthly teleconferences to discuss updates of the material
and plans for new chapters, which are peer-reviewed prior to
publication.
CURRENT CONTENTS AND USAGE
IN THE PUBLIC DOMAIN
The unique content of the AGM, a source for best practices
in robust assay development, is appealing to a growing
audience of researchers interested in enabling early-stage
drug discovery projects. Many publication formats, such
as printed journals and books, are static and, thus, not
amenable to frequent updates. However, the dynamic
eBook format allows for updates to existing chapters and
growth of the AGM. As of December 2017, the AGM contains
46 chapters (up from the original 22 chapters) and a glossary
of common drug discovery terms and definitions. In April
of 2017, the AGM was accessed by 131 countries, with
the majority of readers located in the United States, then
United Kingdom, India, Germany, Canada, Australia, and
Japan, respectively (Figure 2). An analysis of the domains
accessing the AGM indicates that the majority of AGM users
come from .net, .edu, and .com, with a minority coming
from .gov and .org (Figure 3). Most readers from the .net
www.cts-journal.com
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Figure 2 Worldwide access to the Assay Guidance Manual (AGM). The AGM was accessed 39,839 times by readers in 131 countries
during the month of April 2017. The heat map shows the amount of access per country ranging from low (dark blue) to high (red). The
countries colored grey did not access the AGM in April 2017.
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Figure 3 Users of the Assay Guidance Manual (AGM) grouped by domain. The total number of AGM users in the United States during
April are plotted according to domain over a period of 4 years from 2014 through 2017. Although usage is growing in all cases, the majority
of AGM users come from .net, .edu, and .com domains.
domain are likely accessing the AGM from their personal
computers and devices, whereas readers from .edu and
.com domains are probably from academia and industry,
respectively. Although all content is available online, individ-
ual chapters or the entire eBook can be freely downloaded
as pdf files with the current version spanning 1,338 printed
pages. Since the AGM was first published on the NCBI
Bookshelf, worldwide access to the chapters has steadily
increased from about 4,000 per month in 2012 to more than
30,000 per month in 2017 (Figure 4a,b). The AGM chapters
are organized into nine sections in the table of contents,
including: (i) Considerations for Early Phase Drug Discovery;
(ii) In Vitro Biochemical Assays; (iii) In Vitro Cell Based
Assays; (iv) In Vivo Assay Guidelines; (v) Assay Artifacts and
Interferences; (vi) Assay Validation, Operations, and Quality
Control; (vii) Assay Technologies; (viii) Instrumentation; and
(ix) Pharmacokinetics and Drug Metabolism.
The Early Phase Drug Discovery section of the AGM con-
tains a chapter that provides guidelines for planning early
drug discovery and development projects and is particularly
intended to benefit academic researchers, nonprofits, and
other life science research companies.9 The development
of therapeutic hypotheses, validation of targets and path-
ways, and proof-of-concept criteria are discussed. Three
types of projects are highlighted, including: developing a
new chemical entity, repurposing of marketed drugs, and
applying novel platform technology to improve delivery of
currently marketed drugs. In addition to summarizing the
scopes, estimated timelines, and critical decision points for
these projects, the chapter provides details about the types
of assays that should be conducted and cost estimates at
various stages. As such, the chapter can serve as an excel-
lent reference for project planning and for developing grant
proposals. This chapter was first introduced along with the
eBook format on 1 May 2012, and has been updated sev-
eral times to reflect current costs and best practices, most
recently in 2016. In 2017, it was the fourth most popular
chapter and was accessed an average of 1,776 times per
month (Figure 4c).
The In Vitro Biochemical Assays section of the AGM con-
sists of 10 chapters, nine of which were first published on
1 May 2012. The chapters cover a variety of topics
from reagent validation10 and enzymatic11 or immunoassay12
methods, to more specific target types, such as recep-
tors,13,14 kinases,15 proteases,16 histone acetyltransfe-
rases,17 and protein-protein interactions.18 Additionally,
methods are described to determine the mechanism of
action for drug candidates against a target enzyme.19 Five
Clinical and Translational Science
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Figure 4 Worldwide usage of the Assay Guidance Manual (AGM) since 2012. Usage of the AGM has been steadily growing since it was
published as an eBook on the National Library of Medicine, National Center for Biotechnology Information Bookshelf in 2012. Time series
decomposition (using a simple moving average (SMA) with a multiplicative model61) was applied to the access counts for the entire AGM
and selected chapters. Individual components of the decompositions are shown in each plot, with the y-axis for all plots representing
access counts. The trend component was computed using an SMA with a 12-month window. The seasonal component was derived from
the observed time series by dividing by the trend component. The random component was computed by dividing the observed time
series by the seasonal, followed by dividing by the trend components. (a) The total monthly access among all AGM chapters has steadily
increased to >30,000 in 2017. (b) A plot of seasonally adjusted web access for all 46 chapters of the AGM, each shown as a different
color. (c) Among the most widely-accessed chapters is Early Drug Discovery and Development Guidelines: For Academic Researchers,
Collaborators, and Start-up Companies, which was accessed an average of 1,776 times per month in 2017. (d) The Immunoassay Methods
chapter came from the original Eli Lilly and Company Quantitative Biology Manual and was the second most accessed chapter in 2017.
(e) The most popular chapter of the AGM is Cell Viability Assays, which was accessed an average of 11,895 times per month in 2017.
(f) The high-throughput screening (HTS) Assay Validation chapter also originated from the Eli Lilly and Company Quantitative Biology
Manual and has continued to grow in popularity over the past 6 years.
of these chapters are primarily material from the original Eli
Lilly and Company Quantitative Biology Manual for internal
use. Notably, these five chapters have remained popular
among readers over the past 6 years and readership is
continuing to grow for three of them: Mechanism of Action
Assays for Enzymes,19 Receptor Binding Assays for HTS
and Drug Discovery,13 and Protease Assays.16 The other
two original chapters, Immunoassay Methods12 (Figure
4d) and Basics of Enzymatic Assays for HTS,11 were the
second and third most highly accessed chapters of the
AGM in 2017, respectively. Although Immunoassay Methods
was updated in late 2014, the other four chapters have
remained unmodified since 2012. Thus, the important and
fundamental information covered in the original chapters
remains relevant and of high interest to the drug discovery
community.
The largest section of the AGM is the In Vitro Cell Based
Assays section, which comprises 19 chapters. This section
has grown from the initial seven chapters that were intro-
duced in 2012. Collectively the chapters cover concepts rel-
evant throughout the discovery pipeline, from the identifica-
tion and validation of targets and reagents20–22 to advanced
3D model systems and models that can be applied for safety
and toxicity assessments.23,24 Both reproducibility and vali-
dation of assays and reagents are critical for a successful dis-
covery campaign, so a chapter was introduced in 2013 about
the authentication of human cell lines that was co-authored
by Yvonne Reid of the ATCC.20 A number of the chapters
address assays and technologies that can be applied for
primary and secondary screening against targets as diverse
as protein-protein interactions, ion channels, and G-protein-
coupled receptors.25–30 Some of the assay methodologies
www.cts-journal.com
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can be applied to interrogate the regulation of signaling
pathways.31–33 High-content imaging is a powerful methodol-
ogy that enablesmultiplexed readouts from cell-basedmodel
systems. Four chapters focus on such methodologies and
their applications to HTS.32,34–36 Emergingmethodologies are
also covered, such as applications of cellular thermal shift
assays to HTS37 and the use of engineered nucleases in
genomic screening.22 The most highly accessed chapter in
the AGM eBook isCell Viability Assays,38 which was first pub-
lished in 2013 and has continued to attract readers since that
time (Figure 4e). In 2017, Cell Viability Assays was accessed
an average of nearly 12,000 times per month. The chapter
describes a variety of methods that can be applied to esti-
mate the number of viable cells using a plate reader, including
methods that can bemultiplexed with other assays and read-
outs. The remarkable interest in this chapter is likely due to
the increase in use and significance of phenotypic screening
and the universal relevance of this information to biological
discovery projects.39
Later stages of discovery currently require the use of ani-
mal models and the In Vivo Assay Guidelines section of
the AGM provides guidelines for the design, development,
and statistical validation of in vivo assays,40 and methods to
quantify receptor occupancy in rodent models.41 Addition-
ally, the Pharmacokinetics and Drug Metabolism section was
recently introduced with a chapter that provides guidelines
for in vitro and in vivo assessments of absorption, distribu-
tion, metabolism, and elimination and PK properties of lead
candidates.42 More chapters will be introduced on these top-
ics as there is considerable interest in investigational new
drug (IND)-enabling studies amongmany academic and pub-
lic research institutions.
There is considerable attention to reproducibility in
translating basic discovery experiments from published
data into discovery projects.43 Contributions to irrepro-
ducible results, artifactual bioactivity, and poorly tractable
bioactivity can include assay reagents, data analysis meth-
ods, test compounds, instrumentation, and contaminants.
Compound-mediated assay interferences can be highly
reproducible yet intractable sources of bioactivity due to
either nonspecific compound mechanisms of action or
to compound interference with assay readouts.44,45 The
amount of time and resources invested in follow-up stud-
ies of irreproducible false-positives as well as intractable
or artifactual mechanisms of bioactivity can substantially
reduce the productivity of a discovery program, but more
importantly represents lost opportunity costs. The Assay
Artifacts and Interferences section was introduced in 2015
to describe sources of assay artifacts along with strategies
to mitigate them. The first chapter to be introduced, Assay
Interference by Chemical Reactivity,46 was highlighted in
“In The Pipeline,” Derek Lowe’s blog on drug discovery and
the pharma industry.47 Additional chapters focus on inter-
ferences associated with fluorescence and absorbance,48
luciferase reporters,49 and chemical aggregation,50 but more
importantly, their identification and mitigation.
Three of the five chapters comprising the Assay Vali-
dation, Operations and Quality Control section originated
in the Eli Lilly and Company Quantitative Biology Manual:
Data Standardization for Results Management,51 HTS Assay
Validation,52 and Assay Operations for SAR Support.53 Inter-
estingly, the rate of viewership continues to increase for
all three chapters and is shown for the HTS Assay Valida-
tion chapter in Figure 4f. Data analysis templates are avail-
able for download from the chapters: HTS Assay Validation,
Assay Operations for SAR Support, and Minimum Signifi-
cant Ratio (MSR) – A Statistic to Assess Assay Variability.54
These tools allow researchers to perform different types of
analysis procedures, such as plate uniformity and variability
assessments or evaluating reproducibility and robustness of
screening results that are detailed in the chapters. In particu-
lar, the template tools for MSR evaluation have been use-
ful toward understanding and adoption of this less famil-
iar parameter. Briefly, the MSR reflects the intrinsic ability
of a structure activity relationship (SAR) assay to determine
whether the potency (concentration at half-maximal inhibi-
tion or half-maximal effective concentration) measurements
of any two compounds within n-fold are meaningful.55,56 A
robust SAR assay will have an MSR of 3, whereas a weak
assay might have a higher MSR >5. This statistical think-
ing is particularly important to medicinal chemists and phar-
macologists during SAR to determine if the results from a
screening assay allow for a robust differentiation and rank
ordering of compounds. Such analyses also indicate whether
the assay is even capable of guiding meaningful improve-
ments to the potency. The MSR concept is also applied as a
practical quality control tool on the reference (positive con-
trol) compounds for proactively detecting specific assay runs
with significant drift or high variability. Another chapter in this
section provides methods to describe and categorize chem-
ical biology and drug screening assays and their results.57
Instrumentation is an evolving area that enables new fun-
damental measurements, methodologies, pushes detection
limits, and catalyzes discoveries. The Instrumentation sec-
tion of the AGM includes two chapters that describe basic
features of equipment and instrumentation with calculations
that are commonly utilized for HTS.58,59 The Basics of Assay
Equipment and Instrumentation for High Throughput Screen-
ing chapter has been particularly accessed by users coming
from the .edu domain.
ASSAY DESIGN AND DEVELOPMENT WORKSHOPS
The worldwide usage of the AGM demonstrated substantial
interest in assay development methods among the scientific
community and led to the development of anAssay Guidance
Workshop for High-Throughput Screening and Lead Discov-
ery. The AGM eBook serves as a foundation for this work-
shop series, which is led primarily by members of the AGM
Editorial Board. Most of the instructors have 20–30 years
of experience in the field of drug discovery and preclinical
therapeutic development. Ten workshops have been con-
ducted, featuring both single-day and 2-day agendas with
5–17 lectures (Table 1). All workshops emphasize the impor-
tance of assays in guiding and defining the success of a
preclinical discovery program and highlight the AGM as a
resource. Specialized lectures focus on topics such as: tar-
get validation, physiologically relevant models, the devel-
opment and implementation of biochemical and cell-based
assays, analytical technologies, mitigation of assay artifacts
and interferences, lead selection and optimization, safety
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Table 1 Assay guidance workshop for high-throughput screening and lead discovery
Date Location Lectures Organizer(s)
6 February 2015 Rockville, MD 5 National Center for Advancing Translational Sciences
17 July 2015 College Park, MD 7 US Food and Drug Administration, National Center for Advancing Translational Sciences
23 January 2016 San Diego, CA 9 Society for Laboratory Automation and Screening, National Center for Advancing Translational Sciences
5–6 April 2016 College Park, MD 10 US Food and Drug Administration, National Center for Advancing Translational Sciences
27 October 2016 Madison, WI 9 Promega, International Chemical Biology Society, National Center for Advancing Translational Sciences
4 February 2017 Washington, DC 9 Society for Laboratory Automation and Screening, National Center for Advancing Translational Sciences
7 August 2017 Potomac, MD 10 National Center for Advancing Translational Sciences
23 October 2017 Chapel Hill, NC 12 UNC Catalyst for Rare Diseases, Promega, National Center for Advancing Translational Sciences
3 February 2018 San Diego, CA 9 Society for Laboratory Automation and Screening, National Center for Advancing Translational Sciences
26–27 March 2018 Potomac, MD 17 National Center for Advancing Translational Sciences
Ten workshops have been held in locations throughout the United States since February 2015. Both single-day and 2-day agendas have included between 5 and
17 lectures. Many of the events were co-organized with government, industry, and academic partners in addition to international conferences.
and toxicity assays, the assessment of PK and pharmaco-
dynamic properties of lead compounds, as well as assay
statistics and data analysis strategies. Additional lecture
topics have included: the use of a design of experiments
approach for assay development, advanced 3D model sys-
tems, label-free HTS assays with mass spectrometry, high-
content screening, and biophysical methodologies for eval-
uating target engagement. Some workshops have offered
special topic sessions, hands-on data analysis training, and
laboratory tours with demonstrations of equipment. The goal
of each workshop is to provide participants with a broad,
practical perspective on assay development so that they
can (i) improve drug discovery or molecular probe develop-
ment projects, and know where to find further information,
(ii) identify reagents, instrumentation, and methods that are
well-suited to robust assays, (iii) be able to apply robust pri-
mary, orthogonal, and counter assays to a particular bio-
logical target, and (iv) understand critical data analysis con-
cepts. Additionally, participants are provided with oppor-
tunities to seek practical advice about their own areas of
interest.
Although the workshop sizes have ranged from 23 to 169
participants (Figure 5a), the current target number is about
40 participants. It was observed that smaller group sizes
enhance learning by increasing the discussion and interac-
tions between the instructors and participants. Although the
majority of participants are from the United States, individu-
als have also traveled from 14 countries (Figure 5b). The tar-
get audience is individuals involved in bioassay development
for the discovery of drug candidates and chemical probes.
Participants have come from academic, industry, and gov-
ernment sectors (Figure 5c) with experience levels ranging
from students and early career professionals to physicians,
engineers, andwell-established investigators. The high diver-
sity in experiences among both the lecturers and partici-
pants, as well as the sectors and locations from which they
work, typically leads to very interesting questions and dis-
cussions. Some of these discussions have resulted in the
modification of lectures, introduction of new lecture topics,
and growth of the AGM eBook.
Since 2015, three workshops per year have been held in
locations throughout the United States (Table 1). The inau-
gural workshop in February 2015 was held at the NCATS
laboratories in Rockville, MD, and featured five lectures and
a tour of the laboratory equipment. Two subsequent work-
shops were held in 2015 and 2016 at the US Food and Drug
Administration campus in College Park, MD. The workshop
has been offered as a short course by the international
Society for Laboratory Automation and Screening annual
conference since 2016 in both San Diego, CA, and Washing-
ton, DC. In 2016, a workshop was held in association with
the International Chemical Biology Society conference on
Translational Chemical Biology at the Promega campus in
Madison, WI. In 2017, a workshop was held in collaboration
with Promega and the UNC Catalyst for Rare Diseases at the
University of North Carolina in Chapel Hill, NC. Workshops
have also been held in Potomac, MD, in 2017 and 2018. The
combination of limiting workshops to small groups and hold-
ing only three events annually in a single country restricts the
accessibility of this educational format. In order to extend the
workshop material to a wider audience, a collection of high-
quality video recordings of lectures has been developed and
is freely available online (https://ncats.nih.gov/agm-video).
FUTURE DEVELOPMENTS AND ROLE IN TRAINING
DISCOVERY SCIENTISTS
The AGM is established as a world-class resource for guide-
lines and best practices to advance translational sciences;
the preclinical development of novel therapeutics. Both the
eBook and the workshop series have been highlighted in
a recent article by the Society for Laboratory Automation
and Screening Director of Education, Steve Hamilton.60 The
AGM usage metrics indicate growing interest in assay devel-
opment for HTS and lead optimization among researchers
within academic, government, and industrial sectors. It is
important to be aware of new technologies, methodologies,
reporters, reagents, and cell-based model systems. In addi-
tion, concerns about improving reproducibility and tractabil-
ity are shared by researchers worldwide and have led to
important discussions about data analysis, appropriate con-
trols, reagent validation, methodology and study designs,
appropriate model systems, and assay artifacts. To address
this evolving landscape and enable researchers with the nec-
essary knowledge to successfully advance the development
of novel therapeutics, the AGM editors are actively increas-
ing the scope and depth of the eBook, developing educa-
tional videos to supplement the chapters, and enhancing the
workshops.
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Figure 5 Participation in the Assay Guidance Workshop for High-Throughput Screening and Lead Discovery. Ten assay guidance work-
shops have been conducted since 2015. (a) The number of participants in the workshops have varied between 23 and 169, with most
workshops having <50. It was observed that open discussions and learning are enhanced with smaller group sizes. (b) A total of 549
individuals have participated in all 10 workshops and come from 14 countries in addition to the United States. (c) Participants of the
10 workshops come from a variety of settings, including industry, academia, and government. The first workshop and two largest work-
shops were only advertised to employees of the US Government, which is why the majority of the workshop participants are from the
government. DOD, Department of Defense; EPA, Environmental Protection Agency; FDA, US Food and Drug Administration; NIH, National
Institutes of Health; NIST, National Institute of Standards and Technology.
It is important for the AGM eBook to continue as a reli-
able source for up-to-date guidelines and best practices
for robust assay development in quantitative biology and
pharmacology as new topics emerge. Existing chapters will
be updated to include new technologies, techniques, and
trends in the field. Currently, there are nearly 30 new chap-
ters in development that span a broad range of topics, from
guidelines for project management and reviewers of HTS
screening grant proposals to optogenetics and immuno-
genicity assays. Many of the chapters will fit into current sec-
tions of the AGM. For instance, there are three more chapters
in development for the Assay Artifacts and Interferences sec-
tion. Three chapters are also in the works for the Instrumenta-
tion section with a focus on automation and implementation
of methodologies for screening with drug combinations.
Six chapters are in development for the In Vitro Cell Based
Assays section, two of which focus on stem cell pluripotency
assays and guidelines for scaling up pluripotent stem cell
cultures for HTS. Some of the new content will require the
addition of new sections. For instance, in 2018 a Safety and
Toxicity Assays section will be introduced to accommodate
two new chapters, including a complementary chapter to
the Cell Viability Assays chapter that will describe a variety
of in vitro methods to measure dead cells. Another section
will focus on the importance of medicinal chemistry in com-
pound bioactivity analysis and lead optimization and will
include chapters that summarize critical medicinal chemistry
concepts for biologists and other topics, such as quantitative
structure–activity relationship modeling. Related to this will
be a new section focusing on biophysical methodologies for
characterizing target engagement by lead molecules.
The AGM chapters will be enhanced by the introduction of
educational videos about specialized concepts, methodolo-
gies, instrumentation, and data analysis procedures that sup-
port HTS and lead discovery. For example, some chapters
describe specialized automation-compatible equipment not
available in most research laboratories. Knowledge of such
equipment is critical for the successful adaptation of assay
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procedures from the benchtop to a fully automated worksta-
tion, which is a common bottleneck in preclinical research.
An increasing number of researchers are actively develop-
ing assays for HTS as a collaboration. In such cases, the
researchers developing the assays might not operate the
HTS equipment, but such knowledge would benefit the col-
laboration. These videos will also be helpful to a variety of
other individuals, including students, professionals working
across disciplines, and reviewers of HTS grant proposals.
The Assay Guidance Workshop for High-Throughput
Screening and Lead Discovery offers a unique training oppor-
tunity for students and professionals by covering practi-
cal aspects of drug discovery that are not as accessible
from classrooms or the literature. The workshop content is
further enhanced by the diverse backgrounds of the lec-
turers and participants who are able to frame concepts
from different perspectives during formal and informal dis-
cussions. The engagement between scientists from differ-
ent sectors frequently focuses on solving research prob-
lems and sometimes initiating new partnerships. Thus, the
workshops enhance academic-industrial collaborations in
translational biology and medicine. Although the majority of
workshops have had single-day agendas, 2-day events with
wider scopes will be held more frequently in the future. Addi-
tionally, hands-on data analysis sessions will be incorpo-
rated more often so that participants can immediately learn
to apply concepts from the lectures. This will enable partic-
ipants to readily incorporate new analysis strategies within
their own research projects. The series of online workshop
videos will continue to grow with the diversity and scope of
the lectures. This will benefit researchers who are unable to
attend in person or previous participants who would like to
review some aspects.
CONCLUSION
The AGM was initiated as a guide for therapeutic project
teams within a major pharmaceutical company, based on
internal proprietary knowledge assembled from experts
spanning multiple therapeutic disciplines. Recognition that
the value of this manual resulted from the combination of
experiences contributed by more than 100 scientists was
part of the rationale for releasing its contents to the public.
The early vision was that additional contributions from drug
discovery scientists worldwide would add substantial exper-
tise and value. Furthermore, uniting translational scientists in
a precompetitive space would contribute to drug discovery
broadly and benefit everyone. The AGM is intended to serve
as a vehicle for the harmonization of assay design concepts,
definitions, reproducible validated methodologies, and “sta-
tistical thinking,” which is a combination of good science
and common sense with an understanding of variability. Cer-
tainly, both the growing usage of the eBook and popularity of
the workshop series demonstrate a strong interest in robust
biologically, physiologically, and pharmacologically relevant
assays for therapeutic development. New discoveries and
advances in technologies, methodologies, instrumentation,
and data analysis strategies are providing exciting opportu-
nities to support the development of innovative therapeutics.
However, emerging priorities in human health (e.g., Zika virus,
or the opioid addiction crisis) in addition to limitations in time
and research budgets place increasing demands on thera-
peutic discovery projects. Sharing best practice guidelines
will help all researchers do the best possible science; how-
ever, more contributors to the AGM will be required to keep
pace with the new discoveries and advances. Together the
global community can build the AGM as an international trea-
sure of publicly available information to accelerate the trans-
lation of basic research to therapeutics through the training
of scientists.
Acknowledgments. The authors thank Jeff Beck, Charles “Pepper”
Bonney, Penny Burgoon, Laura Carter, Nolan Chase, Adrian Choice, Neal
Cosby, Janice Crum, Suzanne C. Fitzpatrick, Nicholas Gelardi, C. Taylor
Gilliland, Sam Grammer, Steven Hamilton, David Hanley, Nicole Hasel-
wander, Michael Hoffmann, Sandy Ismail, Anne Ketter, Ann Knebel,
Emet LaBoone, Theresa Lamotte, A. Renee Madden, Cindy McConnell,
Dave Morris, Henrike Nelsen, Jim Ostell, Kim Pruitt, Melvin Reichman,
Laura Richards, Meghan Schofield, Hannah Scott, Stephanie Shea, Geoff
Spencer, Ashley Stewart, Amy Wilkinson, and Adam Yasgar for their sup-
port of the AGM.
Source of Funding. This work was supported by the NCATS Divi-
sion of Pre-Clinical Innovation Intramural Program and by the Intramural
Research Program of the NIH, National Library of Medicine. Authors also
acknowledge the NIGMS R13 grant support (5U13MH088095-02) for the
annual editor’s conference on Development of Robust Experimental Assay
Methods (aDREAM) from 2011–2014.
Conflict of Interest. The authors declared no competing interests
for this work.
1. Ledford, H. Translational research: 4 ways to fix the clinical trial. Nature. 477, 526–528
(2011).
2. Fruchter, R., Ahmad, M., Pillinger, M., Galeano, C., Cronstein, B.N. & Gold-von Simson,
G. Teaching targeted drug discovery and development to healthcare professionals. Clin.
Transl. Sci. 11, 277–282 (2018).
3. Gilliland, C.T., Sittampalam, G.S., Wang, P.Y. & Ryan, P.E. The translational science training
program at NIH: introducing early career researchers to the science and operation of
translation of basic research to medical interventions. Biochem. Mol. Biol. Edu. 45, 13–
24 (2017).
4. Assay Guidance Manual. (Eli Lilly & Company and the National Center for Advancing
Translational Sciences, Bethesda, Maryland, 2004).
5. Reese, R.A. Does significance matter? Significance. 1, 39–40 (2004).
6. Antunovic, B. et al. Statistical significance and biological relevance. EFSA J. 9, (2011).
7. Austin, C.P., Brady, L.S., Insel, T.R. & Collins, F.S. NIH molecular libraries initiative.Science.
306, 1138–1139 (2004).
8. Schreiber, S.L. et al. Advancing biological understanding and therapeutics discovery with
small-molecule probes. Cell. 161, 1252–1265 (2015).
9. Strovel, J. et al. Early drug discovery and development guidelines: For academic
researchers, collaborators, and start-up companies. Assay Guidance Manual. (Eli Lilly
& Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
10. Scott, J.E. & Williams, K.P. Validating identity,mass purity and enzymatic purity of enzyme
preparations. Assay Guidance Manual. (Eli Lilly & Company and the National Center for
Advancing Translational Sciences, Bethesda, Maryland, 2004).
11. Brooks, H.B. et al. Basics of enzymatic assays for HTS.Assay Guidance Manual. (Eli Lilly &
Company and the National Center for Advancing Translational Sciences, Bethesda, Mary-
land, 2004).
12. Cox, K.L. et al. Immunoassay methods. Assay Guidance Manual. (Eli Lilly & Company and
the National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
13. Auld, D.S. et al. Receptor binding assays for HTS and drug discovery. Assay Guid-
ance Manual. (Eli Lilly & Company and the National Center for Advancing Translational
Sciences, Bethesda, Maryland, 2004).
14. DeLapp, N.W., Gough, W.H., Kahl, S.D., Porter, A.C. & Wiernicki, T.R. GTPgammaS bind-
ing assays. Assay Guidance Manual. (Eli Lilly & Company and the National Center for
Advancing Translational Sciences, Bethesda, Maryland, 2004).
15. Glickman, J.F. Assay development for protein kinase enzymes. Assay Guidance Man-
ual. (Eli Lilly & Company and the National Center for Advancing Translational Sciences,
Bethesda, Maryland, 2004).
www.cts-journal.com
469
Assay Guidance Manual
Coussens et al.
16. Zhang, G. Protease assays. Assay Guidance Manual. (Eli Lilly & Company and the National
Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
17. Gadhia, S., Shrimp, J.H., Meier, J.L., McGee, J.E. & Dahlin, J.L. Histone acetyltrans-
ferase assays in drug and chemical probe discovery. Assay Guidance Manual. (Eli Lilly
& Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
18. Arkin, M.R., Glicksman, M.A., Fu, H., Havel, J.J. & Du, Y. Inhibition of protein-protein inter-
actions: non-cellular assay formats. Assay Guidance Manual. (Eli Lilly & Company and
the National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
19. Strelow, J. et al. Mechanism of action assays for enzymes. Assay Guidance Manual.
(Eli Lilly & Company and the National Center for Advancing Translational Sciences,
Bethesda, Maryland, 2004).
20. Reid, Y., Storts, D., Riss, T. & Minor, L. Authentication of human cell lines by STR DNA
profiling analysis. Assay Guidance Manual. (Eli Lilly & Company and the National Center
for Advancing Translational Sciences, Bethesda, Maryland, 2004).
21. Martin, S. et al. Cell-based RNAi assay development for HTS. Assay Guidance Man-
ual. (Eli Lilly & Company and the National Center for Advancing Translational Sciences,
Bethesda, Maryland, 2004).
22. Costa, J.R. et al. Genome editing using engineered nucleases and their use in genomic
screening. Assay Guidance Manual. (Eli Lilly & Company and the National Center for
Advancing Translational Sciences, Bethesda, Maryland, 2004).
23. Kijanska, M. & Kelm, J. In vitro 3D spheroids and microtissues: ATP-based cell viability
and toxicity assays. Assay Guidance Manual. (Eli Lilly & Company and the National Center
for Advancing Translational Sciences, Bethesda, Maryland, 2004).
24. Lamore, S.D., Scott, C.W. & Peters, M.F. Cardiomyocyte impedance assays. Assay Guid-
ance Manual. (Eli Lilly & Company and the National Center for Advancing Translational
Sciences, Bethesda, Maryland, 2004).
25. Priest, B.T. et al. Automated electrophysiology assays. Assay Guidance Manual. (Eli Lilly
& Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
26. Arkin, M.R. et al. FLIPR assays for GPCR and ion channel targets. Assay Guidance Man-
ual. (Eli Lilly & Company and the National Center for Advancing Translational Sciences,
Bethesda, Maryland, 2004).
27. McManus, O.B. et al. Ion channel screening. Assay Guidance Manual. (Eli Lilly & Com-
pany and the National Center for Advancing Translational Sciences, Bethesda, Maryland,
2004).
28. Wang, T. et al. Measurement of beta-arrestin recruitment for GPCR targets. Assay Guid-
ance Manual. (Eli Lilly & Company and the National Center for Advancing Translational
Sciences, Bethesda, Maryland, 2004).
29. Wang, T., Li, Z., Cvijic, M.E., Zhang, L. & Sum, C.S.Measurement of cAMP for galphas- and
galphai protein-coupled receptors (GPCRs). Assay Guidance Manual. (Eli Lilly & Company
and the National Center for Advancing Translational Sciences, Bethesda,Maryland, 2004).
30. Wade, M. et al. Inhibition of protein-protein interactions: cell-based assays. Assay Guid-
ance Manual. (Eli Lilly & Company and the National Center for Advancing Translational
Sciences, Bethesda, Maryland, 2004).
31. Garbison, K.E., Heinz, B.A. & Lajiness, M.E. IP-3/IP-1 assays. Assay Guidance Manual. (Eli
Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
32. Trask, O.J. Jr. Nuclear factor kappa B (NF-kappaB) translocation assay development
and validation for high content screening. Assay Guidance Manual. (Eli Lilly & Com-
pany and the National Center for Advancing Translational Sciences, Bethesda, Maryland,
2004).
33. Garbison, K.E., Heinz, B.A., Lajiness, M.E., Weidner, J.R. & Sittampalam, G.S. Phospho-
ERK assays. Assay Guidance Manual. (Eli Lilly & Company and the National Center for
Advancing Translational Sciences, Bethesda, Maryland, 2004).
34. Bray,M.A. & Carpenter, A. Advanced assay development guidelines for image-based high
content screening and analysis. Assay Guidance Manual. (Eli Lilly & Company and the
National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
35. Buchser,W. et al. Assay development guidelines for image-based high content screening,
high content analysis and high content imaging.Assay Guidance Manual. (Eli Lilly & Com-
pany and the National Center for Advancing Translational Sciences, Bethesda, Maryland,
2004).
36. Al-Ali, H., Blackmore, M., Bixby, J.L. & Lemmon, V.P. High content screening with pri-
mary neurons. Assay Guidance Manual. (Eli Lilly & Company and the National Center for
Advancing Translational Sciences, Bethesda, Maryland, 2004).
37. Axelsson, H., Almqvist, H., Seashore-Ludlow, B. & Lundback, T. Screening for target
engagement using the cellular thermal shift assay - CETSA. Assay Guidance Manual. (Eli
Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
38. Riss, T.L. et al. Cell viability assays. Assay Guidance Manual. (Eli Lilly & Company and the
National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
39. Swinney, D.C. & Anthony, J. How were newmedicines discovered? Nat. Rev. Drug Discov.
10, 507–519 (2011).
40. Haas, J. et al. In vivo assay guidelines. Assay Guidance Manual. (Eli Lilly & Company and
the National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
41. Jesudason, C.D., DuBois, S., Johnson, M., Barth, V.N. & Need, A.B. In vivo receptor occu-
pancy in rodents by LC-MS/MS. Assay Guidance Manual. (Eli Lilly & Company and the
National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
42. Chung, T.D.Y., Terry, D.B. & Smith, L.H. In vitro and in vivo assessment of ADME and
PK properties during lead selection and lead optimization - guidelines, benchmarks and
rules of thumb. Assay Guidance Manual. (Eli Lilly & Company and the National Center for
Advancing Translational Sciences, Bethesda, Maryland, 2004).
43. Freedman, L.P., Cockburn, I.M. & Simcoe, T.S. The economics of reproducibility in pre-
clinical research. PLoS Biol. 13, e1002165 (2015).
44. Arrowsmith, C.H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11,
536–541 (2015).
45. Thorne, N., Auld, D.S. & Inglese, J. Apparent activity in high-throughput screening: origins
of compound-dependent assay interference.Curr. Opin. Chem. Biol.14, 315–324 (2010).
46. Dahlin, J.L., Baell, J. & Walters, M.A. Assay interference by chemical reactivity. Assay
Guidance Manual. (Eli Lilly & Company and the National Center for Advancing Transla-
tional Sciences, Bethesda, Maryland, 2004).
47. Lowe, D. Screen carefully. In the Pipeline. <http://blogs.sciencemag.org/pipeline/archiv
es/2015/11/11/screen-carefully>. (2015).
48. Simeonov, A. & Davis, M.I. Interference with fluorescence and absorbance. Assay Guid-
ance Manual. (Eli Lilly & Company and the National Center for Advancing Translational
Sciences, Bethesda, Maryland, 2004).
49. Auld, D.S. & Inglese, J. Interferences with luciferase reporter enzymes. Assay Guidance
Manual. (Eli Lilly & Company and the National Center for Advancing Translational Sci-
ences, Bethesda, Maryland, 2004).
50. Auld, D.S., Inglese, J. & Dahlin, J.L. Assay interference by aggregation. Assay Guidance
Manual. (Eli Lilly & Company and the National Center for Advancing Translational Sci-
ences, Bethesda, Maryland, 2004).
51. Campbell, R.M. et al. Data standardization for results management.Assay Guidance Man-
ual. (Eli Lilly & Company and the National Center for Advancing Translational Sciences,
Bethesda, Maryland, 2004).
52. Iversen, P.W. et al. HTS assay validation. Assay Guidance Manual. (Eli Lilly & Com-
pany and the National Center for Advancing Translational Sciences, Bethesda, Maryland,
2004).
53. Beck, B. et al. Assay operations for SAR support.Assay Guidance Manual. (Eli Lilly & Com-
pany and the National Center for Advancing Translational Sciences, Bethesda, Maryland,
2004).
54. Haas, J.V., Eastwood, B.J., Iversen, P.W., Devanarayan, V. & Weidner, J.R. Minimum sig-
nificant ratio - a statistic to assess assay variability. Assay Guidance Manual. (Eli Lilly
& Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
55. Eastwood, B.J. et al. The minimum significant ratio: a statistical parameter to charac-
terize the reproducibility of potency estimates from concentration-response assays and
estimation by replicate-experiment studies. J. Biomol. Screen. 11, 253–261 (2006).
56. Iversen, P.W., Eastwood, B.J., Sittampalam, G.S. & Cox, K.L. A comparison of assay per-
formance measures in screening assays: signal window, Z’ factor, and assay variability
ratio. J. Biomol. Screen. 11, 247–252 (2006).
57. Vempati, U.D. & Schurer, S.C. Development and applications of the bioassay ontology
(BAO) to describe and categorize high-throughput assays. Assay Guidance Manual. (Eli
Lilly & Company and the National Center for Advancing Translational Sciences, Bethesda,
Maryland, 2004).
58. Jones, E.,Michael, S. & Sittampalam,G.S. Basics of assay equipment and instrumentation
for high throughput screening. Assay Guidance Manual. (Eli Lilly & Company and the
National Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
59. Kahl, S.D., Sittampalam, G.S. & Weidner, J. Calculations and instrumentation used for
radioligand binding assays.Assay Guidance Manual. (Eli Lilly & Company and the National
Center for Advancing Translational Sciences, Bethesda, Maryland, 2004).
60. Hamilton, S. Effective drug discovery begins with the right assay. <https://www.slas.
org/eln/effective-drug-discovery-begins-with-the-right-assay/> (2015).
61. Kendall, M. & Stuart, A. The Advanced Theory of Statistics. Vol 3<http://www.scirp.org/
(S(351jmbntvnsjt1aadkposzje))/reference/ReferencesPapers.aspx?ReferenceID=7491
24> (1983).
C© 2018 The Authors. Clinical and Translational Science
published by Wiley Periodicals, Inc. on behalf of the
American Society of Clinical Pharmacology and Thera-
peutics.
This is an open access article under the terms of the
Creative Commons Attribution-NonCommercial License,
which permits use, distribution and reproduction in any
medium, provided the original work is properly cited and
is not used for commercial purposes.
Clinical and Translational Science
470
